Results 61 to 70 of about 4,805 (202)

A phase 1 study of the safety, pharmacokinetics and pharmacodynamics of escalating doses followed by dose expansion of the selective inhibitor of nuclear export (SINE) selinexor in Asian patients with advanced or metastatic malignancies

Therapeutic Advances in Medical Oncology, 2022
Purpose: This phase 1 study aims to evaluate the tolerability and the recommended phase 2 dose of selinexor in Asian patients with advanced or metastatic malignancies.
Jingshan Ho, Valerie Heong, Wei Peng Yong, Ross Soo, Cheng Ean Chee, Andrea Wong, Raghav Sundar, Yee Liang Thian, Anil Gopinathan, Mei Yan Pang, Priscillia Koe, Santhiay Nathan Jeraj, Phyu Pyar Soe, Mu Yar Soe, Tiffany Tang, Matthew C.H. Ng, David W.M. Tai, Tira J.Y. Tan, Hongmei Xu, Hua Chang, Yosef Landesman, Jatin Shah, Sharon Shacham, Soo Chin Lee, Daniel S.W. Tan, Boon Cher Goh, David S.P. Tan   +26 more
doaj   +1 more source

Exportin 1 Inhibitor Combined With Venetoclax Induces Apoptosis in Myelodysplastic Syndrome by Mitochondria‐Induced Apoptosis Pathway

Journal of Clinical Laboratory Analysis, EarlyView.
Inhibition of XPO1 is a promising modality in the treatment of MDS, especially when combined with Venetoclax, which activates mitochondria‐mediated apoptosis and could be a potential target for MDS therapy. ABSTRACT Background Myelodysplastic syndromes (MDS) are clonal hematopoietic malignancies that pose a serious health threat.
Xiaohan Liu, Lei Huang, Junzhu Wang, Yixuan Guo, Hongli Shen, Xianghong Zhao, Lanzhu Yue, Zhaoyun Liu, Rong Fu   +8 more
wiley   +1 more source

Establishment and Verification of UPLC-MS/MS Technique for Pharmacokinetic Drug–Drug Interactions of Selinexor with Posaconazole in Rats

Drug Design, Development and Therapy, 2021
Chen-jian Zhou,1 Hui-jun Wang,2 Chun-yan Zhou,2 Chao-fan Li,2 Ming-Jia Zhu,2 Xiang-jun Qiu2 1Department of Pharmacy, Wenzhou Central Hospital, Wenzhou, 325027, People’s Republic of China; 2School of Basic Medical Sciences, Henan University of ...
Zhou C, Wang H, Zhou C, Li C, Zhu MJ, Qiu X   +5 more
doaj  

Phase I study of selinexor in combination with dexamethasone, ifosfamide, carboplatin, etoposide chemotherapy in patients with relapsed or refractory peripheral T-cell or natural-killer/T-cell lymphoma

Haematologica, 2020
Selinexor is a selective inhibitor of nuclear export with anti-cancer properties. We performed a phase I study to determine the safety and maximum tolerated dose of selinexor when combined with high-dose dexamethasone, ifosfamide, carboplatin and ...
Tiffany Tang, Peter Martin, Nagavalli Somasundaram, Cindy Lim, Miriam Tao, Eileen Poon, Maica JD. Yunon, Shu Q. Toh, Sean X Yan, Mohamad Farid, Jason Y. Chan, Soon T. Lim   +11 more
doaj   +1 more source

Real-world experience with selinexor-containing chemotherapy-free or low-dose chemotherapy regimens for patients with relapsed/refractory acute myeloid leukemia and myeloid sarcoma

Frontiers in Pharmacology, 2023
Introduction: Treatment of relapsed or refractory acute myeloid leukemia (R/R AML) and myeloid sarcoma (MS) has presented challenges for decades. Studies on selinexor in combination with various standard or intensive chemotherapy regimens for the ...
Xiwen Tong, Jie Jin, Bin Xu, Shuai Su, Li Li, Mengyuan Li, Yizhou Peng, Xia Mao, Wei Huang, Donghua Zhang   +9 more
doaj   +1 more source

CRISPR‐Cas9 Genome‐Wide Screening in Paediatric Cancer: Functional Genomics for Target Discovery and the Improvement of Existing Therapies

Medicinal Research Reviews, EarlyView.
ABSTRACT CRISPR‐Cas9 genome‐wide screening has been instrumental towards identifying novel targets for drug discovery in cancer research. However, much of this research has centred specifically on adult cancers, with paediatric cancers being underserviced by current research and screening.
Steven He, Patrick Connerty, Antoine de Weck   +2 more
wiley   +1 more source

Selinexor (KPT-330) in Combination with Immune Checkpoint Inhibition in Uveal Melanoma: A Phase 1B Trial [PDF]

Journal of Immunotherapy and Precision Oncology
Introduction Uveal melanoma remains a disease with aggressive behavior and poor prognosis despite advances in clinical management. Because monotherapy with immune checkpoint inhibitors has led to limited improvement in response rates, combination with ...
Mohamed A. Gouda, Abdulrazzak Zarifa, Yali Yang, Bettzy Stephen, Serdar A. Gurses, Ashabari Sprenger, Yanyan Tian, Mohamed H. Derbala, Isabella Glitza Oliva, Funda Meric-Bernstam, Sapna P. Patel   +10 more
doaj   +1 more source

Targeting Nuclear Export Proteins in Multiple Myeloma Therapy. [PDF]

, 2020
Multiple myeloma (MM) is an incurable malignancy of plasma cells with a clinical course characterized by multiple relapses and treatment refractoriness.
Chari, Ajai, Lancman, Guido, Theodoropoulos, Nicholas   +2 more
core   +1 more source

Benefit of selinexor dose reduction on outcomes with selinexor, bortezomib and dexamethasone in patients with lenalidomide‐refractory multiple myeloma: Subgroup analysis of the BOSTON trial

British Journal of Haematology, EarlyView.
A subgroup analysis of efficacy, safety and QOL in patients who received selinexor in combination with bortezomib and dexamethasone (SVd) with and without selinexor dose reduction and who had lenalidomide‐refractory disease in the phase 3 BOSTON trial showed improvements in efficacy, quality of life (QOL) and safety outcomes with selinexor dose ...
Sosana Delimpasi, Ivan Špička, Jason P. Butler, Don A. Stevens, Mercedes Gironella Mesa, Ceri Bygrave, Giovanni Marino Merlo, Charles la Porte, Meletios A. Dimopoulos   +8 more
wiley   +1 more source

The European Society for Medical Oncology (ESMO) Congress 2016: Highlights and summary of selected abstracts in gynecologic cancers [PDF]

, 2017
The 2016 ESMO Congress held in Copenhagen, Denmark (07–11th October 2016) brought together over 20,000 attendees from 127 countries. The highlight of the meeting for the gynecological track was the presentation at a Presidential session of the ENGOT-OV16/
Ledermann, JA, Miller, RE
core